P-18 ANTI-HBC POSITIVITY IS AN INDEPENDENT PREDICTIVE FACTOR FOR HCC DEVELOPMENT AND SHOULD BE INCORPORATED TO THE HCC RISK SCORE PREDICTION MODEL IN ADVANCED FIBROSIS

No After hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs), the sustained viral response increased to 95%, although it may be lower in advanced fibrosis. Continuous follow-up of HCV cured individuals is essential. In that context, identifying higher risk populations to intensify its surveillance is important to allow early hepatocellular carcinoma (HCC) detection and optimize costs. Our group previously demonstrated a risk association between anti-HBc and HCC, since the presence of hepatitis B virus infection has oncogenic properties. Our objective is to evaluate the HCC risk score prediction model accuracy in our population and investigate the inclusion of anti-HBc positivity in the model. This is a retrospective, observational, descriptive and analytic study in a series of cases in which 365 HCV patients were evaluated. Demographic, clinical and laboratory data were obtained through electronic medical records. The HCC risk score was applied before and after SVR. A total of 21 patients had HCC diagnosis after RVS (5.75%). The variables associated with higher HCC occurrence were: genotype 3 (p=0.025), AST pretreatment (p=0.026), elastography > 10kPa (p=0.003) and advanced fibrosis (p=0.016). Among advanced fibrosis patients, positive Anti-HBc (p=0.047) was an independent predictor factor associated with HCC. After univariated analysis, genotype 3 and positive anti-HBc were predictive factors of HCC occurrence in advanced fibrosis. When applying the HCC risk score before treatment, the area under the receiver operating characteristic curve (AUROC) was 0.731, while after SVR had a slightly lower value (0.723) – Figure 1A. After incorporating anti-HBc to all other variables used in HCC risk score, the accuracy was 0.744 – Figure 1B. The HCC risk score is a validated prediction model of HCC occurrence before and after SVR. Anti-HBc positivity might be a good candidate to be incorporated to the model.

Authors

Institutions

Publication Details

Journal
Annals of Hepatology
Published
2024-12-01
DOI
https://doi.org/10.1016/j.aohep.2024.101632
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-18 ANTI-HBC POSITIVITY IS AN INDEPENDENT PREDICTIVE FACTOR FOR HCC DEVELOPMENT AND SHOULD BE INCORPORATED TO THE HCC RISK SCORE PREDICTION MODEL IN ADVANCED FIBROSIS

Patrícia Momoyo Zitelli, Marcus Vinícius De Acevedo Garcia Gomes, Alexandre Trazzi, Rosa Maria Nascimento Marcusso et al.
Annals of Hepatology
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
article

P-18 ANTI-HBC POSITIVITY IS AN INDEPENDENT PREDICTIVE FACTOR FOR HCC DEVELOPMENT AND SHOULD BE INCORPORATED TO THE HCC RISK SCORE PREDICTION MODEL IN ADVANCED FIBROSIS

Patrícia Momoyo Zitelli, Marcus Vinícius De Acevedo Garcia Gomes, Alexandre Trazzi, Rosa Maria Nascimento Marcusso, Mário Guimarães Pessôa, Isabela Bodaczny Taliberti, Diogo Delgado Dotta, Betania da Silva Rocha, Eduardo J. M. Nascimento, M. Sobral
article en

Abstract

No After hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs), the sustained viral response increased to 95%, although it may be lower in advanced fibrosis. Continuous follow-up of HCV cured individuals is essential. In that context, identifying higher risk populations to intensify its surveillance is important to allow early hepatocellular carcinoma (HCC) detection and optimize costs. Our group previously demonstrated a risk association between anti-HBc and HCC, since the presence of hepatitis B virus infection has oncogenic properties. Our objective is to evaluate the HCC risk score prediction model accuracy in our population and investigate the inclusion of anti-HBc positivity in the model. This is a retrospective, observational, descriptive and analytic study in a series of cases in which 365 HCV patients were evaluated. Demographic, clinical and laboratory data were obtained through electronic medical records. The HCC risk score was applied before and after SVR. A total of 21 patients had HCC diagnosis after RVS (5.75%). The variables associated with higher HCC occurrence were: genotype 3 (p=0.025), AST pretreatment (p=0.026), elastography > 10kPa (p=0.003) and advanced fibrosis (p=0.016). Among advanced fibrosis patients, positive Anti-HBc (p=0.047) was an independent predictor factor associated with HCC. After univariated analysis, genotype 3 and positive anti-HBc were predictive factors of HCC occurrence in advanced fibrosis. When applying the HCC risk score before treatment, the area under the receiver operating characteristic curve (AUROC) was 0.731, while after SVR had a slightly lower value (0.723) – Figure 1A. After incorporating anti-HBc to all other variables used in HCC risk score, the accuracy was 0.744 – Figure 1B. The HCC risk score is a validated prediction model of HCC occurrence before and after SVR. Anti-HBc positivity might be a good candidate to be incorporated to the model.

Annals of HepatologyVol. 29
Instituto de Infectologia Emílio Ribas (BR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
Openalex Percentile: Top 59%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.